Consortium Québécois sur la découverte du médicament
Overview
CQDM is a non-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D that accelerates translation of leading-edge discoveries into vaccines, therapeutics and diagnostics addressing unmet medical needs while generating significant benefits for the Canadian economy. CQDM deploys R&D funding programs that focus on accelerating the translation of innovation into socio-economic outcomes and health benefits for our population.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| 48Hour Discovery | Mar 2021 | Grant | Co-investor |
| NuvoBio | Mar 2026 | Accelerator | Co-investor |
| Focai Bio | Mar 2026 | Accelerator | Co-investor |
| TATUM Bioscience | Jun 2026 | Grant | Co-investor |
| VascuBio Innovation | Nov 2025 | Grant | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Consortium Québécois sur la découverte du médicament based?
Consortium Québécois sur la découverte du médicament is headquartered in Quebec.
When was Consortium Québécois sur la découverte du médicament founded?
Consortium Québécois sur la découverte du médicament was founded in 2008.
How many portfolio companies does Consortium Québécois sur la découverte du médicament have?
Consortium Québécois sur la découverte du médicament has 35 portfolio companies in Caplight's dataset.
What are some companies in Consortium Québécois sur la découverte du médicament's portfolio?
Portfolio companies visible on Caplight include 48Hour Discovery, NuvoBio, Focai Bio, TATUM Bioscience, VascuBio Innovation.
What was Consortium Québécois sur la découverte du médicament's most recent investment shown here?
Consortium Québécois sur la découverte du médicament's most recent investment in this portfolio sample was in TATUM Bioscience in 2026.
What sectors does Consortium Québécois sur la découverte du médicament focus on?
Consortium Québécois sur la découverte du médicament focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Media, Entertainment & Gaming, AI, Data & Cloud Infrastructure, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, AI, Data & Cloud Infrastructure, Enterprise Software, Enterprise Software, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Consortium Québécois sur la découverte du médicament focus on?
Consortium Québécois sur la découverte du médicament typically invests at the MultiStage stage.
What is Consortium Québécois sur la découverte du médicament's AUM?
Consortium Québécois sur la découverte du médicament's assets under management are estimated between $0.0 and $50.0M.